COVID-19, antiviral drug, nucleoside analog, mutagenesis, animal model, HAE
sars-cov2, sotrovimab, Non human primate
EV-A71, Capsid binder, Structure-based design, Structure-activity relationships, Heterocyclic compounds
Enterovirus, Capsid binder, Broad-spectrum, Structure-activity relationships, Fused bicycles, heterocyclic compounds